NOS-2 signaling and cancer therapy

Related Experiment Video

Updated: May 21, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Ka Bian1, Farshid Ghassemi, Alex Sotolongo

  • 1Department of Biochemistry and Molecular Biology, George Washington University, School of Medicine, Washington, DC, USA. bcmfxm@gwu.edu

IUBMB Life
|June 21, 2012
PubMed

Insights

Nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) signaling roles in cancer remain unclear. Targeting inducible nitric-oxide synthase (iNOS) and normalizing sGC-cGMP pathways may offer novel cancer therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • The nitric oxide (NO) and cyclic guanosine monophosphate (cGMP) signaling pathway's role in tumor biology is complex and debated.
  • High concentrations of NO, produced by inducible nitric-oxide synthase (iNOS or NOS-2), can be cytotoxic or apoptotic, while its signaling functions vary by cell type and tissue.
  • Tumors comprise neoplastic cells (parenchyma) and supporting nonmalignant tissues (stroma), each with distinct NO biology.

Purpose of the Study:

  • To review the expression of NOS-2 in tumor and surrounding cells.
  • To summarize research outcomes regarding the NO/sGC/cGMP pathway in cancer therapy.
  • To propose therapeutic strategies targeting this signaling axis.

Main Methods:

  • Literature review focusing on NOS-2 expression in tumor microenvironments.
  • Analysis of existing research on the NO/sGC/cGMP pathway in cancer.
  • Synthesis of findings to evaluate therapeutic potential.

Main Results:

  • NOS-2 expression varies significantly between tumor cells and the tumor microenvironment.
  • The dual role of NO (cytotoxic vs. signaling) contributes to the ambiguity surrounding its impact on cancer.
  • The NO/sGC/cGMP pathway's components and functions differ across various cellular compartments within tumors.

Conclusions:

  • A normally functioning soluble guanylate cyclase (sGC)-cGMP signaling axis may be crucial for preventing and treating malignant tumors.
  • Inhibiting iNOS overexpression and the tumor inflammatory microenvironment, alongside normalizing sGC/cGMP signaling, presents a potential alternative to conventional cancer treatments.
  • Further characterization of NO/sGC/cGMP signaling in both tumors and surrounding tissues is essential for developing targeted therapies.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Non-Canonical Wnt Signaling Pathways01:41

Non-Canonical Wnt Signaling Pathways

Wnt is a zygotic effect gene that is expressed during very early embryonic development. It regulates various processes in animals starting from early development through the adult stage, such as organogenesis in the embryo and maintenance of neuronal and blood stem cells. Wnt proteins can induce a wide variety of intracellular pathways depending upon the specific abilities of different Wnt ligands to form a complex with shared and cognate receptors in the presence of different co-receptors. The...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...